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ABSTRACT: Photodynamic therapy (PDT) is an established clinical treatment modality for cancer and other non-malignant 
diseases, requiring the combined use of a photosensitizer (PS), light irradiation of a specific wavelength for each PS, and oxy-
gen to generate reactive oxygen species (ROS) responsible for destroying the tumour. We use in vitro PDT with the photosen-
sitizer (PS) redaporfin to generate prophylactic whole-cell antitumour vaccines and evaluate the immunogenicity of two opti-
mization protocols. In the first protocol, 4T1 cells were incubated with the PS, underwent different doses of PDT to modulate 
apoptotic/necrotic cell death. After a 24 h post-PDT incubation, the cells were irradiated with picosecond UV to generate the 
vaccine. Different treatment groups (Apoptosis/UV; Necrosis/UV; UV control) of BALB/c mice were subcutaneously vacci-
nated with 3.00 x 106 treated cells. After a week, they were subcutaneously inoculated with 350,000 viable cells for the tumour 
challenge. The results did not have statistical significance nor showed immunogenic effect between the treatment groups and 
the negative control. In the subsequent protocol, we changed to the CT26 cell line, and the post-PDT incubation time was 
shortened to 4 h without UV picosecond irradiation. The cells were incubated with the PS, and underwent a low-dose PDT to 
induce apoptosis. After 4 h, the vaccines were generated and the different groups of BALB/c mice were subcutaneously inocu-
lated with 500,000 or 300,000 apoptotic cells. The positive control was subcutaneously vaccinated with 500,000 mitoxantrone 
(MTX) treated cells. After a week, the mice were challenged with a subcutaneous inoculation of 350,000 viable cells. There 
was not a statistical significant difference between the treatment groups and the negative control but the vaccines with 500,000 
apoptotic cells show some immunogenic effect in tumour growth, comparable to the effect of the MTX vaccines. 
ABBREVIATIONS 
APC, antigen-presenting cell; ATP, adenosine triphosphate; 
CRT, calreticulin; DAMP, damage-associated molecular pat-
tern; DC, dendritic cell; DMEM, Dubbelco's modified Eagle's 
medium; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic 
acid; ER, endoplasmic reticulum; F2BMet, 5,10,15,20-Tetrakis 
(2,6-fluoro-3-N-methylsulphamoylphenyl) bacteriochlorin; 
FBS, foetal bovine serum; FWHM, full width at half maximum; 
HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
buffer; HMGB1, high mobility group box 1; ICD, immuno-
genic cell death; LED, light-emitting diode; MHC, major histo-
compatibility complex; MTX, mitoxantrone; PBS, phosphate-
based saline; PenStrep, penicilin-streptomycin; PDT, photody-
namic therapy; PI, propidium iodide PS, photosensitizer; ROS, 
reactive oxygen species; UV, ultraviolet. 
INTRODUCTION 
Cancer is responsible for one in seven deaths, worldwide, 
being one of the leading causes of death. In 2012, there were 
estimated 14.1 million new cases, a number that is expected 
to keep increasing due to the growth and aging of global 
population.1 This pathological process is developed when 
the normal growth of cells, which is kept under control by 
inhibitors in the surrounding environment, in the extracellu-
lar matrix, and on the surface of neighbouring cells, is dis-
rupted leading to an abnormal growth and spreading.1,2 
During their evolution to a malign state, tumour cell acquire 
characteristics that allow tumour growth and metastatic 
dissemination. They do not need the stimulation of external 
growth signals, being capable of producing their own; are 
insensitive to growth suppressors; have pro-survival mecha-
nisms that evade cell death; have limitless replicative poten-
tial; can sustain angiogenesis; are able to migrate and invade 
other tissues. In the last decade, two emerging hallmarks 
have been added to this list: reprogramming of energy me-
tabolism in order to most effectively support cancer prolif-
eration and evading the immune system.2 
Photodynamic therapy (PDT) is an established clinical 
treatment modality for cancer and other non-malignant 
diseases.2–5 This technique presents several advantages over 
the standard anticancer therapies (i.e., surgery, radiotherapy, 
and chemotherapy) because it is minimally invasive, it has a 
low mutagenic potential, low systemic toxicity, and it tar-
gets specifically the tumour tissue.2,3,6  
PDT requires only the use of a photosensitizer (PS), light 
irradiation of a specific wavelength for each PS, and oxy-
gen. These components are harmless individually, but their 
combination can generate reactive oxygen species (ROS) 
that are responsible for the destruction of the tumour.4,5,7–9 
The treatment involves the systemic or topical administra-
tion of the PS, which accumulates in the tumour tissue that 
will be irradiated2,4,10 after an optimized drug-to-light inter-
val. The PS, among other characteristics,5,7 has to have a 
high absorption peak between 650 and 850 nm, a range 
known as the phototherapeutic window (spectral region 
where the tissues are the most transparent), balancing deeper 
penetration of tissues (longer wavelengths) with providing 
enough energy to excite the oxygen to its singlet state 
(shorter wavelengths). When the PS is irradiated with visible 
light, the molecule is activated from its ground state to a 
short-lived single excited state (1PS*) which can undergo 
intersystem crossing to form a relatively long-lived excited 
2 
triplet state (3PS*). In type I photochemical processes, the 
3PS* participates in electron or hydrogen-atom transfer reac-
tions with biological substrates to produce radical forms that 
act as intermediates to generate reactive oxygen species. In 
type 2 photochemical processes the 3PS* transfers energy 
directly to molecular oxygen to form the phototoxic excited-
state singlet oxygen (1O2).2,6,7,11,12 
The ROS generated by PDT are able to lead to cell death via 
different pathways, that are not mutually exclusive: auto-
phagy, necrosis, and/or apoptosis.5,12 Autophagy is a process 
of degeneration of the macromolecular components of the 
cytoplasm and organelles, which are surrounded by the 
autophagosome. Following the merger of the lysosome with 
autophagosome, its content is degraded.12 Cell death by 
autophagy in PDT-treated cells is still controversial, since it 
plays a role in either inhibiting or stimulating cell death, 
following the PDT treatment.2,10,12 Generally, autophagy acts 
as a pro-survival strategy in cells capable of apoptosis, and 
promotes cell death in apoptosis-deficient cells.2 However, it 
appears that therapy-prompted autophagy in tumour cells 
has the ability to regulate the release/exposure of multiple 
danger signals, also called damage-associated molecular 
patterns (DAMPs; molecules that usually remain inside live 
cells but are released from or exposed at the surface of dying 
cells), that are associated to the inflammatory response. The 
inhibition of this cell death pathway prevents one of these 
DAMPs: the release of adenosine triphosphate (ATP) by 
dying cells, showing that autophagy plays an important role 
in the immune system.12–14 Necrosis is one of the primary 
reactions to PDT, observed at cellular level.15 It consists in a 
pathological process where the cytosolic contents are spilled 
to extracellular space due to loss of membrane integrity and 
complete degradation of the cell.12,16 This type of cell death 
takes place above the threshold of resistance of cells treated 
with non-physiological disturbances, thus it is often ob-
served after PDT with high light and photosensitizer 
doses.2,12,16 Typical necrotic changes involve an overload of 
intracellular Ca2+ (from the passive influx caused by dam-
aged membrane, and from the outflow from the endoplasmic 
reticulum (ER)), activation of many deoxyribonucleic acid 
(DNA) nucleases, and lysosomal damage, which conse-
quently leads to the total cell lysis.5,12 The release of the 
disintegrated organelles results in a strong response from the 
immune system and the onset of inflammation, and this is 
why the release of DAMPs was originally connected to this 
cell death pathway.12,17 However, the notion that necrosis is 
immunogenic16 while apoptotic tumour cells do not show 
the same effective response in activating the immune system 
has been invalidated by recent reports.2,17,18 Apoptosis is the 
other major cell death caused in response to PDT5: a type of 
programmed cell death responsible for eliminating un-
wanted cells causing disturbances in their integrity or elicit-
ing inflammatory responses. It is easily recognized by the 
changes in cellular morphology (shrinkage, blebbing of the 
membrane, chromatin condensation and DNA fragmenta-
tion).12 Apoptosis is a very complex type of cell death that 
can occur via different pathways, depending on the cellular 
organelles involved in the process. The best known mecha-
nisms of apoptosis are the extrinsic (death receptor) and the 
intrinsic (mitochondrial) pathways.2,12 The extrinsic pathway 
operates on the membrane receptors (e.g., tumour necrosis 
factor receptors) that by binding their respective ligands, 
induce the activation of caspases. The intrinsic pathway is 
activated by an increase of ROS, disruption of the ion trans-
port, or the increase of Ca2+ in the cytoplasm, leading to the 
release of pro-apoptotic molecules (e.g., cytochrome c) into 
the cytoplasm. This release is controlled by proteins of the 
Bcl-2 family, being favoured when two pro-apoptotic mem-
bers of the Bcl-2 family, Bax and Bak, are oligomerized and 
inserted in the mitochondrial membrane. When cytochrome 
c is in the cytosol it is able to initiate the activation of the 
cascade of caspases.2,5,6,12 
However, the efficiency of PDT lies in two other mecha-
nisms, besides the direct cytotoxicity through the types of 
cell death mentioned above: damage to tumour vasculature 
that deprives the tumour of oxygen and nutrients, and an 
acute inflammatory response by recruiting and activating 
immune cells.2,4,8,9,11,12,16,19 The standard PDT treatment 
stimulates inflammation causing a strong immune response 
that is not only localized at the treatment site, involving both 
the innate and adaptive immune systems at a systemic level. 
Innate immunity in response to PDT is characterized by an 
increased expression of pro-inflammatory cytokines, neu-
trophil infiltration into the treated tumour site, and activation 
of the complement cascade.2,4,10,15,19 This is followed by the 
activation of the adaptive immune system where PDT en-
hances the activation and maturation of APCs (dendritic 
cells (DCs) in particular)2,4,5,15 that are responsible to phago-
cytise tumour cells destroyed by PDT, process the tumour-
specific peptides, and present them as antigens on their 
membranes in the context of major histocompatibility com-
plex (MHC) class II molecules. This presentation allows the 
recognition of the antigens by CD4+ helper T cells that in 
turn will sensitise CD8+ cytotoxic T cells, as well as the 
generation of CD4+ and CD8+ memory T cells that will 
recognize and target tumour-specific antigens leading to 
immunity.4,6 It has also been acknowledged the importance 
of MHC class I molecules, that are found to be downregu-
lated in tumour cells (one of the causes responsible for poor 
antitumour immunity),2 for CD8+ cytotoxic T cells to recog-
nize and destroy tumour cells.2,5 
Furthermore, PDT treatment of tumour cells is able to in-
duce DAMPs that can trigger antigen presenting cells 
(APCs), which is related to antitumour immunity through 
the establishment of CD8+ T cell cytotoxic and memory 
responses, even in the absence of CD4+ T cells.2,4,5 More 
attention has been brought to these molecules because of 
their association with the immunogenicity of dying tumour 
cells, namely an immunogenic form of apoptosis that pre-
sents the same biological hallmarks of “tolerogenic” apop-
tosis but is able to expose/release DAMPs and elicits an 
immune response against tumours. This lead to a screening 
of cytotoxic agents/modalities in cancer treatment that can 
elicit immunogenic cell death (ICD), in order to develop 
strategies to reinforcing the therapeutic effect of the treat-
ment.2,20 The main DAMPs that characterize ICD are the 
exposure of calreticulin (CRT) on the membrane, the trans-
location to the membrane’s surface or extracellular release 
of heat shock proteins, release of the high mobility group 
box 1 (HMGB1) and other end-stage degradation products 
(e.g., ATP), and secretion of inflammatory cytokines.2,10,17,21 
However, it is accepted that a tumour cell subjected to a 
cancer treatment undergoes ICD, if there is subsequent CRT 
exposure, HMGB1 release, and ATP secretion.10,12,14,18,20 
CRT is a Ca2+-binding protein mainly located in the ER 
lumen acting in the correct folding of proteins, regulation of 
Ca2+ homeostasis, and signalling. It is also responsible in the 
assistance of the proper assemble of MHC class I molecules 
and the load of antigen, along with other functions outside 
the ER like regulation of nuclear transport and cell prolifera-
tion and migration. When CRT is translocated to the mem-
brane and exposed on the surface of tumour cells undergo-
ing ICD, it acts as an “eat-me” signal and simplifies their 
engulfment by DCs leading to tumour antigen presentation 
and tumour-specific CD8+ cytotoxic T cell responses.2,17,20 
HMGB1 is an abundant nuclear non-histone chromatin-
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binding protein. It affects several nuclear functions such as 
DNA repair and recombination, stabilization of nu-
cleosomes, and transcription, but HMGB1 also has cytoso-
lic17 and extracellular17,20 roles, where it mediates autophagy 
and acts as a secreted cytokine (not as DAMP), respectively. 
It is accepted that when a cancer treatment induces ICD, 
dying tumour cells release HMGB1 causing an intense in-
flammatory response by stimulating the production of pro-
inflammatory cytokines from innate immune cells but the 
specific role of HMGB1 in ICD is still unclear. Recent 
studies claim that these multiple behaviours might be influ-
enced by the redox state of HMGB1, which changes its 
activity between chemoattractant DAMP (fully reduced 
HMGB1), pro-inflammatory cytokine-inducing DAMP 
(disulphide bond-possessing HMGB1), and inactivated 
DAMP (fully oxidized HMGB1; it still maintains chemoat-
tractant properties). However, it is worth of note that 
HMGB1 reducible states can also interfere with antitumour 
immunity through its involvement in tumour tissue invasion 
and metastasis, in decreasing antitumour immunogenicity, 
and in promoting resistance to chemotherapeutics and irra-
diation.2,17,20 The extracellular release of ATP (a nucleotide 
usually found in the ER) modulates different cellular func-
tions (i.e. survival, death, adhesion, proliferation, differen-
tiation, and mobility) but it is well known as a “find-me” 
signal that can be secreted through several mechanisms by 
dying cells which attracts APCs. The presence of extracellu-
lar ATP on the cell surface is also responsible for the regula-
tion of DC migration, and activation of antitumour immune 
responses.2,17 
To elicit ICD, the combined action of two components is 
required in order to trigger the intracellular mechanisms: 
production of ROS and ER stress.10,17,21 The ER is an eu-
karyotic organelle responsible for vital sensing, biosynthetic 
and signalling functions, as well as for the synthesis, folding 
and post-translational modifications of a large of number of 
proteins. If the ER homeostasis is disturbed, it causes an 
imbalance between protein folding load and capacity: this is 
termed ER stress. The first response is activating a pro-
survival pathway that tries to restore the homeostasis but 
when the ER stress is too severe that pathway turns into one 
of pro-death.17 
This combination suggested that PDT treatments had the 
potential to induce a strong immune response through 
ICD.10,17,21 And that was in fact the case, though most re-
search on PDT-induced DAMP exposure used Photofrin as a 
PS, Garg et al.22 published one of the most important dis-
coveries in the field of ICD.22,23 They investigated the expo-
sure of DAMPs using PDT with hypericin, a PS which 
associates with the ER membranes, and the results obtained 
showed the first type II ICD inducer described in the litera-
ture.22 Treatments that induce primary ER stress are known 
as type II inducers and show a stronger immune response 
compared to treatments that induce ER stress as secondary 
effect through damage to other cellular targets (type I ICD 
inducers).10,17 In PDT, the ER stress can be modulated with 
the use of a PS that localizes preferably in the ER, that when 
excited causes a massive production of ROS (focused ROS-
based ER stress), inducing ICD.7,17 
One of the most interesting developments that resulted from 
the continued investigation for improved efficacy and ex-
panded use of PDT is to exploit this immune response in the 
generation of antitumour vaccines.3,24,25 Vaccines contain 
agents incapable of harming the host but able to trigger an 
immune response by boosting the immune system’s natural 
ability to protect and defend the body against infections or 
dangers from growth of abnormal cells, as is the case of 
antitumour vaccines. These are considered to be therapeu-
tic,3,26,27 if they act as treatment of an existing cancer, like a 
recent vaccine approved by the FDA to treat metastatic 
prostate cancer; or are prophylactic,24 if their aim is to pre-
vent the development of cancer in healthy individuals, such 
as a vaccine that is against human papilloma virus, and other 
vaccine against hepatitis B virus. 25,28 Antitumour vaccines 
have minimal toxicity and offer different strategies that 
target the immune system,29 being able to use: DC that are 
able to express immunostimulatory cytokines in parallel 
with antigen presentation;29,30 tumour-associated antigens as 
therapeutic targets (peptide-based vaccines) inoculated with 
an appropriate adjuvant;29,31 or viral/plasmid DNA vectors 
that deliver antigens or antigen fragments (genetic vac-
cines);29 and tumour cells (autologous or allogeneic) that are 
usually subjected to lethal doses of radiation, or tumour cell 
lysates, to inoculate the antigens exposed on the surface of 
the cells for tumour-specific immunization;26,29,32,33 In this 
last type of antitumour vaccines it is important to say that 
most tumour cells are poorly immunogenic, and may not be 
able to stimulate the immune system as expected.16 
Nevertheless, PDT is able to increase the immunogenicity of 
these cells through induction of ICD and the development of 
PDT-generated vaccines3,24,26 is a promising strategy to 
enhance immunostimulation to the level of systemic PDT,15 
and proves to be more advantageous over antitumour vac-
cines generated through X-ray exposure, ultraviolet (UV) 
irradiation, hyperthermia, or freeze-thaw lysates, due to the 
highly amplified immunogenicity triggered by DAMPs.2,5  
Our work explores the possibility of generating a prophylac-
tic antitumour vaccine using PDT. The PS used was a halo-
genated bacteriochlorin recently described (5,10,15,20-
Tetrakis (2,6-fluoro-3-N-methylsulphamoylphenyl) bacteri-
ochlorin, or F2BMet)7–9 named redaporfin (that highly local-
izes in the ER) to evaluate its immunogenicity. Previous 
work in our group with redaporfin showed a systemic im-
mune response in the control of metastasis34 in BALB/c 
mice. Thus, it was of interest to seek ways of developing 
strategies that potentiate systemic PDT using redaporfin. To 
assure a greater coverage of potential antigens the protocols 
developed during this project are intended to generate 
whole-cell vaccines with homogeneous populations of cell 
death (apoptotic or necrotic), and assess which method will 
be able to better stimulate the immune system of BALB/c 
mice against a tumour challenge. 
EXPERIMENTAL SECTION 
Reagents 
The growth media for cell culture used were RPMI-1640 
media (purchased from Sigma-Aldrich) and Dubbelco's 
Modified Eagle's Medium (DMEM; purchased from Sigma-
Aldrich), for 4T1 cell line and CT26 cell line, respectively. 
Both media were supplemented with 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid buffer 
(HEPES) 10 mM, and sodium bicarbonate 10mM, pur-
chased from Sigma-Aldrich. Foetal bovine serum (FBS) and 
penicillin-streptomycin (PenStrep) were purchased from 
Gibco. Milli-Q water was deionised with a Millipore Milli-
Q water purification system. 
Potassium phosphate dibasic, potassium chloride, sodium 
phosphate dibasic, and sodium chloride were purchased 
from Sigma-Aldrich and used to prepare the phosphate-
buffered saline (PBS) solution. PBS Ca/Mg was supple-
mented with calcium chloride dehydrate and magnesium 
chloride hexahydrate, also purchased from Sigma-Aldrich. 
Trypsin-EDTA solution (10x), Trypan Blue, dimethyl sul-
foxide (DMSO), and Propidium Iodide (PI; ≥ λ4%) were 
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purchased from Sigma-Aldrich. Hoechst 33342 stain was 
purchased from Life Technologies. 
Redaporfin (Supplementary Figure 1A) was kindly provided 
by Luzitin, SA. Mitoxantrone (MTX; Supplementary Figure 
1B) was purchased from Sigma-Aldrich. 
Equipment 
All the procedures dealing with the manipulation of cells, 
growth media, PBS solutions, and other reagents and mate-
rials were performed in a Thermo Scientific MSC-
Advantage laminar flow hood. 
All weight measurements were made at room temperature 
on a previously calibrated Kern ALJ 220-5DNM analytical 
balance. 
Culture flasks, cell scrapers, conical centrifuge tubes, mi-
cropipettors, and ComfoPette used were purchased from 
Orange Scientific. Glass Pasteur pipettes, standard tips, and 
1.5 mL/2.0 mL tubes were purchased from Frilabo. The 
material used to deal with cells was previously sterilised in 
the AJC Uniclave 88 autoclave, before entering the hood 
environment. 
An Olympus CKX41 inverted microscope equipped with an 
Olympus U-RFLT50 power supply unit was used to observe 
cell morphology and fluorescent dyes to assess cell viability. 
Absorption spectra of redaporfin stock samples were re-
corded in UV-visible Recording Spectrophotometer (Shima-
dzu). The samples were measured in quartz cuvettes with an 
optical path of 1 cm. 
The light source used was a light-emitting diode (LED) from 
Marubeni (model L740-66-60-550), with an output power of 
410 ȝW, emission maximum at 740 nm with FWHM = 25 
nm. The fluence of the LED was verified with a Coherent 
LaserCheck power meter, choosing a wavelength of 749 nm 
with the filter position on “< 10 ȝW”. 
Preparation of redaporfin stock solution 
The 1mM stock solution of redaporfin (Supplementary 
Figure 1A) was prepared by dissolving 1.70 mg of redapor-
fin in 1.5 mL of DMSO and subjected to 35 kHz in a Bande-
lin Sonorex TK52 ultrasonic bath for 30 s to avoid the for-
mation of clusters. 
The concentration of the stock solution was calculated 
through its absorption spectra (Supplementary Figure 2) 
using the Beer-Lambert Law (equation 1): 
(1) A = ε l c  
whereμ A is the absorbance at the peak position, ε (cm-1 M-1) 
is the molar attenuation coefficient, l (cm) is the path length, 
and c (mol/L or M) is the molar concentration of the 
Redaporfin sample. The molar absorption coefficient is 
ε749=1.21x105 cm-1 M-1 and the path length is 1 cm. The 
molar concentration of the stock is obtained when multiply-
ing the molar concentration of the sample by the dilution 
factor of the sample from the stock solution in DMSO. A 
DMSO sample was used as a “blank”. 
The stock solution was kept refrigerated, at 4ºC, protected 
from light exposure. 
Preparation of MTX stock solution 
The 1 mM stock solution of MTX was prepared by dissolv-
ing 1.03 mg of MTX in 2 mL of PBS, and stirred. The stock 
solution was kept refrigerated, at 4ºC. 
Cell culture 
The cell lines used were 4T1mouse mammary tumour cells 
and CT26 mouse colon carcinoma cells. 4T1 cells were 
cultured in RPMI medium supplemented with 10% of FBS 
and 1% of PenStrep, and CT26 cells were cultured in 
DMEM medium supplemented with 10% of FBS and 1% of 
PenStrep. Both growth media were prepared as described in 
the Supplementary Information. The cells were grown in 
sterile T75 flasks with filter cap in the Thermo Scientific 
BB15 incubator, at 37ºC in a humidified environment con-
taining 5% carbon dioxide (CO2). The cells’ growth was 
maintained for 2 to 3 days; when the cells reached 80% 
confluence, they were detached with Trypsin. 
In vitro PDT of 4T1 cells 
The vaccines were generated based on the procedures de-
scribed by Korbelik et al.3 and Garg et al.,18 with some 
modifications. Firstly, 1.00x106 4T1 cells were seeded in 
T75 flasks with 10 mL of growth medium, and left to incu-
bate overnight so the cells could adhere to the flask. The 
following day, the medium was removed and replaced with 
15 mL of the solution of redaporfin in growth medium in the 
required concentration. 
The PS was incubated for 18-20 h before it was removed, 
and the cells were washed twice with 5 mL of PBS to re-
move the excess of redaporfin that was not internalized by 
the cells. After washing the cells, 10 mL of growth medium 
was added to the cells that were then exposed to the LED 
light for a calculated time interval (Δt) until it achieved the 
intended light dose, using equation 2. Higher light doses 
were used to induce necrotic cell death and lower light doses 
were used to induce apoptotic cell death.2,34,35 
(2) 
                                             
The cells were left to incubate for 24h, and then were sub-
jected to an additional procedure before generating the 
whole-cell vaccines (Supplementary Scheme 1A). 
Additional procedure 
X-ray irradiation. An experiment with 300,000 live cells 
was conducted to see if the conditions of X-ray irradiation 
available were viable to increase cell death. The cells were 
collected with the growth medium and were centrifuged at 
3,000 rpm for 8 minutes. Then, the supernatant was re-
moved and the cells were washed in 2 mL of PBS, followed 
by another centrifugation at 3,000 rpm for 5 minutes. After-
wards, the supernatant was discarded, and the cells were re-
dispersed in 100 ȝL of PBS and transferred to a 200 ȝL tube 
in order to be centrifuged again at 3,000 rpm for 5 minutes. 
The supernatant was removed leaving the pellet in the tube. 
The sample was then irradiated by a Philips PW 1830/00 
(X-ray generator) with a Mo tube (Kα, Ȝ=0,71073 Å). The 
generator was operated with the white spectrum of the tube, 
without filter or monochromator, with a power of 2kW. The 
tube with the pellet of cells was set in the arrangement dis-
played in Supplementary Figure 3, while being irradiated 
with X-rays for 2 h. 
UV picosecond irradiation. The cells were scraped off and 
collected with the growth medium similarly to the protocol 
for X-ray irradiation. Then the cells were centrifuged and 
washed with PBS three times, as described in the Supple-
mentary Scheme 1B, to isolate the pellet of treated cells in 
the tube. The sample was then set in the arrangement dis-
played in Supplementary Figure 4 while being irradiated by 
an EKSPLA PL2143A/SH/TH/FH picosecond laser at 
Ȝem=266 nm. Cells used for UV control vaccines were ad-
ministrated redaporfin but were not subjected to PDT. The 
UV irradiation protocol for these cells suffered some altera-
tions because it involved killing all the cells, needing a 
higher UV dose: the density of cells irradiated had to be 
divided in half to be subjected to UV irradiation (Supple-
mentary Scheme 1C). After irradiating, the cells in each tube 
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were re-dispersed in 100 ȝL of PBS and the volumes were 
coupled. Similarly to the test experiment for X-ray irradia-
tion, 300,000 live cells were collected with the growth me-
dium, isolated as described in Supplementary Scheme 1B, 
irradiated, re-dispersed in RPMI, and left to incubate in a 
flask to assess cell viability after UV irradiation. 
In vitro PDT of CT26 cells 
For this protocol, only one type of cell death was induced: 
apoptosis. Two different cell densities, 1.35x106 and 
750,000 CT26 cells, were seeded in T75 flasks with 10 mL 
of growth medium, and left to adhere to the flask by incu-
bating overnight. The next day, the medium was removed 
and replaced with 15 mL of 5 ȝM of redaporfin in growth 
medium. 
As described for the in vitro PDT of 4T1 cells, the PS was 
incubated for 18-20 h before it was removed, and the cells 
were washed twice with 5 mL of PBS Ca/Mg to remove the 
excess of PS that was not internalized by the cells. After 
washing the cells, 10 mL of DMEM was added to the cells 
that were then exposed to 0.35 J/cm2 of LED irradiation. 
The time of exposure (Δt) was calculated with equation 2.  
The cells incubated for 4 h, then were scraped off the flask 
and collected with the growth medium to be isolated accord-
ing to the steps for centrifugation and wash, described in 
Supplementary Scheme 2B. The pellet of treated cells in the 
tube was used to generate the vaccines. 
Positive control 
To compare the immunogenicity of the generated vaccines, 
we prepared a protocol with a whole-cell vaccine generated 
with MTX, which is known to induce ICD17,21. 
750,000 CT26 cells, were seeded in T75 flasks with 10 mL 
of growth medium, and left to incubate overnight. The next 
day, when the cells adhered to the flask, the growth medium 
was removed and replaced with 15 mL of a 5 ȝM solution of 
MTX in DMEM. The MTX solution was incubated for 24 h. 
The cells were then scraped off and collected with the MTX 
in order to be centrifuged and washed with PBS, four times. 
This process is represented in detail in Supplementary 
Scheme 3B. In between centrifugations, it was obtained a 
blue pellet that contained the cells with internalized MTX 
(blue). After this process of isolation, the pellet of cells in 
the tube was used to generate MTX vaccines. 
Animals and vaccine protocol 
All the in vivo studies were performed in BALB/c female 
mice, in accordance with local ethical guidelines. In each set 
of experiments, the mice were randomly assigned to four 
different treatment groups (n=6). Tumour volume was cal-
culated using equation 3. 
(3) 
                                    
where: a is the major axis of the tumour, b is the minor axis 
of the tumour. 
The follow-up of the animals for both experiments can be 
found in the Supplementary Information, starting from the 
day the vaccine was inoculated (day 0). 
4T1. The experiment was performed in 11 to 16-week old 
mice. In the PDT followed by UV irradiation (Apop-
tosis/UV or Necrosis/UV) and UV control treatment groups, 
the animals were vaccinated subcutaneously (using a 21G 
needle) on the left flank with 3.00x106 treated cells re-
dispersed in 200 ȝL of PBS. The negative control group was 
inoculated subcutaneously on the left flank with 200 ȝL of 
PBS. The animals were rested a week and then inoculated 
subcutaneously (using a 26G needle) on the right flank with 
a challenge of 350,000 viable 4T1 cells re-dispersed in 
RPMI without FBS or PenStrep supplements. The animals 
were sacrificed when the major axis of the tumour reached 
1.5 cm, or at 33rd day after vaccination. 
CT26. The experiment was performed in 15 to 16-week-old 
mice. In the PDT treatment groups, PDT500 and PDT300, the 
animals were vaccinated subcutaneously (using a 26G nee-
dle) on the left flank with 500,000 and 300,000 treated cells, 
respectively, re-dispersed in 200 ȝL of PBS. The MTX 
treatment group was vaccinated subcutaneously on the left 
flank with 500,000 treated cells re-dispersed in 200 ȝL of 
PBS. The negative control group was inoculated subcutane-
ously on the left flank with 200 ȝL of PBS. The animals 
were rested a week and then inoculated subcutaneously 
(using a 26G needle) on the right flank with a challenge of 
350,000 viable CT26 cells re-dispersed in DMEM without 
FBS or PenStrep supplements. The animals were sacrificed 
when the major axis of the tumour reached 1.5 cm, or at 31st 
day after vaccination. 
Statistical analysis 
The results for the evaluation of tumour growth are ex-
pressed as means ± SEM and statistical difference was ana-
lysed with a two-tailed, two-sample Student’s t-test with 
unequal variance, α=0.05. 
RESULTS 
Modulation of 4T1 cell death with PDT 
Several conditions of different PS concentrations and light 
doses were experimented on 4T1 cells while simulating the 
in vitro PDT protocol described for this cell line.  
The type of cell death obtained for all of the different condi-
tions experimented is listed in Supplementary Table 1, or-
dered from the lowest to highest ROS factor associated 
(calculated using equation 4). 
(4)  OSfactor = 
Light
dose  (
 
cm2 )     edaporfin   ȝM  
After assessing which conditions achieved the highest per-
centage of cell death without losing homogeneity, the ex-
periments with the chosen values for concentration of 
redaporfin and amount of light dose (see Table 1) were 
repeated thrice to assure reproducibility. Figure 1 shows the 
two types of cell death induced, 24 h after PDT. 
Table 1. PDT conditions to modulate type of cell death 
 
[F2BMet] 
(μM) 
Fluence 
rate 
(mW/cm2) 
Light 
dose 
(J/cm2) 
Cell death 
(%) 
Apoptosis 1.26 ≈ 1.0 0.15 80 – 90 
Necrosis 1.26 ≈ 2.0 2.00 > 90 
 
 
Figure 1.Types of cell death induced by the in vitro PDT proto-
col. (A) Apoptotic cells 24 h after PDT. (B) Necrotic cells 24h 
after PDT. 
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Generation of 4T1 whole-cell vaccines 
Adapting the method described by Korbelik et al.,3 24 h 
following the in vitro PDT protocol and before generating 
the vaccines, the cells were subjected to an additional pro-
cedure to increase the percentage of cell death. 
The first option experimented was X-ray irradiation. Since 
the conditions referred in the literature3 were not available, 
the procedure was carried out as described in the experimen-
tal section. After the X-ray irradiation, the cells were re-
dispersed in RPMI and transferred to a T25 flask to be left 
to incubate overnight. The next day, when evaluating the 
flasks it was obvious that there was not a cytotoxic effect, 
but visibly helped proliferation, as shown in Figure 2. The 
control group (Figure 2A) underwent the same procedures 
except the X-ray irradiation, when the cells just remained 
without growth medium for 2 h (time of the irradiation). 
 
Figure 2. Cell viability 24h after X-ray irradiation. (A) Control 
group. (B) Cells irradiated for 2h. 
The X-ray irradiation was put aside, and replaced with UV 
irradiation, which is known to induce ICD.21,24 As described 
in the experimental section, a test experiment was conducted 
to assess cell viability after UV picosecond irradiation. The 
viability of cells which were irradiated for different doses of 
UV radiation, after 48 h, is shown in Supplementary Figure 
5. The effect of UV irradiation is visible in all of the condi-
tions experimented, as high levels of apoptosis. However, 
there are considerable amounts of viable cells in the lower 
doses (0.78 and 1.56 J) that decrease when the dose is in-
creased (3.90 J), to a point where no viable cells were found 
(7.80 and 15.6 J). These values were obtained through equa-
tion 5, by varying the time of exposure to UV irradiation. 
(5)    ( ) =   (W)   Δt  s  
where: DT is the total dose of UV radiation that the cells 
were subjected to, P is the power of the laser (takes into 
account the energy of one pulse, and that the laser shoots 10 
pulses per second), Δt is the amount of time that the cells are 
irradiated. 
After repeating the experiment, simulating the full in vitro 
PDT protocol followed by UV picosecond irradiation (Sup-
plementary Scheme 1A, B), the optimal conditions for the 
highest amount of cell death were summarized in Table 2. 
The additional procedure after PDT was able to increase cell 
death in approximately 10%. 
Figure 3 (A, B and C, D) show the viability of 4T1 cells 
after combining PDT with UV irradiation to generate the 
vaccines. As mentioned above and seen in Supplementary 
Figure 5, the type of death induced by UV irradiation is 
apoptosis. This, however, does not affect to a great extent 
the homogeneity of the necrotic cell group (see Figure 3) 
because the PDT protocol had already induced > 90% of cell 
death (see Table 1). 
Table 2. Conditions to generate 4T1 whole-cell vaccines 
 PDT UV  
 
[F2BMet] 
(μM) 
Fluence 
rate 
(mW/cm2) 
Light 
dose 
(J/cm2) 
Total 
dose 
(J) 
Cell 
death 
(%) 
Apoptosis  
/ UV 
1.26 ≈ 1.0 0.15 11.7 90 
Necrosis 
/ UV 
1.26 ≈ 2.0 2.00 11.7 ≈ 100 
UV 
control 
1.26 0 0 36.0 * 70 – 80 
* Sum of the two doses of 18.0 J of irradiation to each half of 
the 3.00 x 106 4T1 cells needed for the vaccine. 
 
 
Figure 3. The viability of the different protocols for generating 
the vaccines. Apoptosis/UV: (A) cells 24h after UV irradiation; 
(B) stained cells 24h after UV irradiation. Necrosis/UV: (C) 
cells 24h after UV irradiation; (D) stained cells 24h after UV 
irradiation. UV control: (E) cells 24h after a total of 36.0 J of 
UV irradiation; (F) stained cells 24h after a total of 36.0 J of 
UV irradiation. The fluorescent dyes are Hoechst in blue, and 
PI in red. 
The last type of vaccines generated was the UV control 
group. These cells were administrated the PS but did not 
undergo PDT (Supplementary Scheme 1C). After incubating 
the redaporfin for 18-20 h, the cells were collected and 
isolated. As all cells were alive, the protocol used for UV 
irradiation following the PDT was not enough to kill enough 
cells. So, the UV dose was increased, raising the percentage 
of cell death as well. The maximum dose experimented was 
an UV irradiation of 36.0 J (the equivalent to 1 h of irradia-
tion; see Supplementary Figure 6D), achieving a higher rate 
of cell death. The UV control group obtained the best results 
in cell death as seen in Figure 3, using the protocol de-
scribed for UV control in the Experimental section (condi-
tions summarized in Table 2; Supplementary Scheme 1C 
and Supplementary Figure 6F) for preparing the cells for 
irradiation, followed by irradiating each half of the total 
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density of cells for the vaccine with 18.0 J (half the total 
dose of UV radiation). 
In vivo evaluation of the efficacy of PDT-
generated 4T1 whole-cell vaccines 
To test if our protocol was able to induce immunogenicity 
and enhance the host antitumour immunity after generating 
the vaccines as described in the Experimental Section, the 
animals were inoculated the vaccines (day 0), and after a 
week they were challenged with 350,000 live cells (day 7). 
The measurements and statistics of tumour growth for this 
protocol are displayed in Supplementary Tables 2 – 5. Stu-
dent’s t-test statistical analysis results are summarized in 
Supplementary Table 6. 
After a week of the challenge (day 14), all groups had ani-
mals that developed tumours in the challenge site, and the 
measurement of the tumour sizes revealed that the tumours 
on the A/UV group were on average smaller than the nega-
tive control tumours (see Graphic 1; Supplementary Tables 
5 and 2), but N/UV and UV control groups already pre-
sented tumours larger than the control ones. On the 21st 
post-vaccination day, it showed that all the animals in the 
A/UV, N/UV, and UV control groups showed tumours 
larger than the control groups indicating that the protocol 
was not showing the desired effect. This behaviour contin-
ued to be visible until the day of the 33rd day endpoint, when 
the experiment ended and all animals were sacrificed. 
Graphic 1. Evaluation of 4T1 tumour growth 
 
The graphic represents the average tumour growth of the dif-
ferent vaccination groups. The error bars represent the SEM. 
The statistical analysis (Supplementary Table 6) showed that 
despite the difference in averages, there was not a statistical 
significant difference when compared to the negative control 
group. 
The UV control group always showed the largest tumours in 
average (Graphic 1) and also the largest SEM (Supplemen-
tary Table 3). At the 28th post-vaccination day, four of the 
mice had already started showing tumour growth on the 
vaccination site; one of them had developed an intramuscu-
lar tumour and reached the endpoint of 1.5 cm on the 27th 
post-vaccination day. Another one of these mice reached the 
same endpoint at the 31st post-vaccination day. On the 33rd 
post-vaccination day, there were four mice, two of them 
with a tumour growing in the vaccination site. 
In the Necrosis/UV group, there were not animals that de-
veloped tumours in the left flank (vaccine), and all reached 
the 33rd day endpoint. In average, the tumours from these 
animals were always larger than the control tumours but 
they seemed to grow slower than the other two treatment 
groups until the 33rd post-inoculation day where it was seen 
that the tumours were similar in size to the ones from the 
UV control group. 
In the last group of treatment, Apoptosis/UV, the size of the 
tumours initially appeared to be smaller than the ones in the 
control group. One week after the challenge (day 14) this 
was the only group that had two animals which had not 
developed tumours on the challenge site; however, it already 
had four mice with tumours on the vaccination site. After 21 
days of the vaccination, the average size of the tumours in 
this group had surpassed the ones in the control and in the 
Necrosis/UV groups, and all the mice presented tumours on 
the left flank. One of the mice was sacrificed at the 27th 
post-vaccination day to avoid unnecessary pain to the ani-
mal, since the tumour had invaded the muscle and was af-
fecting its mobility even if the tumour had not reached 
1.5cm endpoint. Two other mice were sacrificed 32 days 
after the vaccine inoculation without reaching any of the 
endpoints because it was not possible to sacrifice them the 
next day. 
Graphic 2 represents the survival curve of the animals in the 
different vaccination groups, until the 33rd day endpoint, 
when all mice were sacrificed and the experiment ended. 
Graphic 2. Kaplan-Meier representation of the in vivo 
experiment with 4T1 vaccines 
 
Deaths represented in the different groups were sacrifices of 
the animals that reached one of the endpoints. At the 33rd day, 
the experiment ended and all the animals were sacrificed. 
Generation of CT26 whole-cell vaccines 
For this protocol we decided to study only the effect of 
apoptotic vaccines because it was the type of cell death that 
initially showed some difference in tumour growth in the 
former protocol, and this introduced the possibility of veri-
fying the induction immunogenic apoptosis using PDT. 
Other change that was introduced was the shortening of 
post-PDT incubation time to 4 h, since we observed that 
immunogenicity was lost after 24 h. 
We also focused on generating two vaccines with different 
number of apoptotic cells to see if there was any effect 
caused by the number of cells used in the vaccine. The in 
vitro PDT conditions for inducing apoptosis in CT26 cells 
are described in Table 3. The in vitro PDT experiments were 
repeated three times, for both cell densities, and showed that 
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after 4 h post-PDT it was possible to see 70–80 % of the 
cells were dead or dying (Figure 4). At this timepoint, the 
cells were isolated according to the protocol (simplified in 
Supplementary Scheme 2) to generate the two types of 
vaccine: PDT500, vaccines with 500,000 cells re-dispersed in 200 ȝL of PBS; and PDT300, vaccines with 300,000 cells per 
200 ȝL of PBS. Another experiment was conducted to check 
the viability of these conditions, after 24h (Supplementary 
Figure 7). This raised the levels of cell death to > 90 %. 
The positive control for this experiment was MTX. The cells 
were incubated 24 h with 5 and 10 ȝM of MTX dissolved in 
DMEM to assess cytotoxicity. However, these concentra-
tions resulted in the same 30 to 40 % cell death by apoptosis 
(Figure 5). Therefore, to generate the vaccines we used a 
MTX concentration of 5 ȝM. After the 24h incubation, the 
cells were isolated according to the protocol (simplified in 
Supplementary Scheme 3), generating a pellet of CT26 cell 
with a light blue tint, which showed that the cells had inter-
nalized MTX. After the isolation of the pellet with treated 
cells, the vaccines were generated by re-dispersing 500,000 
cells in 200 ȝL of PBS. 
Table 3. Conditions to generate CT26 whole-cell vaccines 
 PDT MTX  
 
[F2BMet] 
(μM) 
Fluence 
rate 
(mW/cm2) 
Light 
dose 
(J/cm2) 
[MTX] 
(μM) 
Cell 
death 
(%) 
Apoptosis 4.21 ≈ 1.0 0.35  70 – 80 
MTX 
   5 30 – 40 
 
 
Figure 4. The viability of the different protocols for PDT-
generated vaccines. PDT500: (A) cells 4h after PDT protocol; 
(B) stained cells 4h after PDT protocol. PDT300: (C) cells 4h 
after PDT protocol; (D) stained cells 4h after PDT protocol. 
 
 
Figure 5. CT26 cells (A) before and (B) 24h after incubation of 
a 5ȝM solution of MTX in DMEM. The arrows in (B) indicate 
the places where the blebbing of the membrane of apoptotic 
cells is visible. 
In vivo evaluation of the efficacy of PDT-
generated CT26 whole-cell vaccines 
Following the generation of the vaccines, as described in the 
Experimental Section, the animals from the different groups 
were inoculated with the vaccines (day 0), and after a week 
they were challenged with 350,000 live cells (day 7). The 
evaluation of tumour growth in each group is represented in 
Graphic 3. The measurements and statistics of tumour 
growth for this protocol are displayed in Supplementary 
Tables 7 – 10. Student’s t-test statistical analysis results are 
summarized in Supplementary Table 11. 
At the 14th post-vaccination day, all the animals in the con-
trol group (n=5) already presented tumour formation, while 
in the treatment groups only 2 mice had developed tumour 
from the challenge (Supplementary Tables 7-10). At this 
point, the tumours from animals in the MTX group were the 
smallest in average. Overall, the control group was the one 
with the largest tumours, and 4 out of 5 animals were sacri-
ficed before reaching the end of the experiment (shown in 
the survival curves represented in Graphic 4), at the 31st 
post-vaccination day. 
Graphic 3. Evaluation of CT26 tumour growth 
 
The graphic represents the average tumour growth of the dif-
ferent vaccination groups. The error bars represent the SEM. 
The statistical analysis (Supplementary Table 11) showed 
that there was not a statistical significant difference when 
the treatments were compared to the negative control group, 
except for MTX on day 28. This was a single event that was 
not observed before or after this timepoint. 
The group inoculated with the MTX vaccines, was the only 
group that did not develop a secondary tumour from the 
vaccination protocol. The tumour growth was always infe-
rior to the control group but it only shows to have statistical 
significant difference (p < 0.05) on the 28th post-vaccination 
day. On this day, Graphic 3 shows a decrease in the average 
of tumour growth due to the sacrifice of two of the mice that 
had reached the 1.5 cm endpoint on day 24. At the end of 
the experiment 2 out of the 4 mice in this group also reached 
the 1.5 cm endpoint. 
The average tumour growth in PDT500 group was very simi-
lar to the MTX group, until the 24th post-vaccination day 
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(Graphic 3) when one mouse from the PDT500 group had 
already been sacrificed (day 21) and two mice from the 
MTX group reached the 1.5 cm endpoint. The decrease seen 
after the 28th post-vaccination day in the average of tumour 
growth of the PDT500 group is a result of the sacrifice of two 
animals that reached the 1.5 cm endpoint on day 28. In this 
group (n=6), 5 animals developed a secondary tumour in the 
vaccination site (4 from day 14, and the other from day 21); 
the mouse which did not develop a tumour from the vaccine 
was present in the group that reached the end of the experi-
ment (n=3), and was a singularity that did not develop a 
tumour from the challenge with live CT26 cells (acted as 
“vaccinated”). 
The last group of treatment was PDT300. One mouse from 
this group is not accounted in the statistical analysis, be-
cause it developed an intramuscular tumour from the vacci-
nation that reached the 1.5 cm endpoint before the challenge 
tumour. This made the follow-up of tumour growth unviable 
to the analysis, and reducing the number of animals in this 
group (n=5). The growth of the tumour was in average 
slightly lower to the control group except for the timepoint 
on day 24, when 2 mice reached the 1.5 cm endpoint and 
were sacrificed. Tumours caused by the vaccine appeared in 
3 out of the 5 animals, on the 14th post-vaccination day. As 
seen in the other treatment groups, the decrease in tumour 
growth observed after the 28th post-vaccination day is due to 
the sacrifice of one mouse that reached the 1.5 cm endpoint. 
Only 2 out of the 5 animals reached the 31st day endpoint. 
Graphic 4. Kaplan-Meier representation of the in vivo 
experiment with CT26 vaccines 
 
Deaths represented in the different groups were sacrifices of 
the animals that reached one of the endpoints. At the 31st day, 
the experiment ended and all the animals were sacrificed. 
DISCUSSION 
The targeted action of PDT is one of its advantages but it 
also brings disadvantages when dealing with metastatic 
lesions.5 This requires the development of treatments that 
are able to progress from local to systemic treatments. 
PDT is able to produce changes in tumour cells that lead to 
an increased exposure of surface antigens which are able to 
stimulate the host immune system2,4,5 Our group has re-
ported results consistent with this fact using redaporfin, 
where mice cured with the optimized vascular-PDT protocol 
were re-challenged 3 months later with CT26 cell in the 
opposite thigh to the PDT treatment. 67% of the cured mice 
rejected the re-challenge and remained tumour-free for at 
least 70 days.34 Moreover, in the same study Rocha et al.34 
disclosed that the PDT protocol also plays an important role 
in the stimulation of the adaptive immune system. 
One of the tasks of this project was to compare the effi-
ciency of apoptosis vs. necrosis in inducing ICD. The first 
protocol used mice mammary tumour 4T1 cell line which is 
a highly malignant and very poorly immunogenic.36 Our 
group had not yet conducted experiments with this cell line, 
so we performed experiments with several conditions vary-
ing light doses, and PS concentrations in order to modulate 
the type of cell death. To each combination of redaporfin 
concentration and light dose we associated a ROS factor, in 
order to help defining an outcome associated to a dose of 
PDT. After ordering from the lowest to highest ROS factor 
(Supplementary Table 1), it was easy to see the “safe” 
threshold of the combinations that could be used to obtain 
necrosis ( OS factor ≥ 1.2645) or apoptosis ( OS factor ≤ 
0.1897), homogeneously. Using the same concentration of 
redaporfin (1.26 ȝM), to induce necrosis it was needed a 
light dose of 2 J/cm2 while to induce apoptosis it was used 
0.15 J/cm2. This is concordant to what expected from the 
literature2,12,34,35 where necrosis is achieved using higher 
light doses, and apoptosis is achieved with lower light doses. 
Since our purpose was to generate whole-cell vaccines, one 
of our concerns was having an additional procedure after 
PDT that excluded the risk of tumour formation because of 
the vaccine. Korbelik et al.3 used lethal X-ray doses to de-
stroy all viable cells; however, we had not access to the 
same conditions of X-ray irradiation described in the paper, 
and had to adapt to the conditions available with an X-ray 
generator used for crystallography. The conditions used 
proved to be insufficient in destroying cancer cells, and even 
seemed to promote cell proliferation. This result might be 
explained by the observation that mammalian cells have the 
ability to spontaneously recover from sublethal X-ray dam-
age.37 Replacing the X-ray irradiation with UV picosecond 
irradiation, given that UVC radiation (100-290 nm) is identi-
fied as an ICD inducer21,24, we used a picosecond laser emit-
ting in this range (266 nm). With this method we were able 
to induce apoptosis, which is the expected cell death path-
way for UVC irradiation,21 and increase the cytotoxicity 
following PDT treatment. 
Tumour response to the PDT-generated vaccine was not 
favourable; the tumour volume in animals inoculated with 
treated 4T1 cells (PDT/UV and UV control) were in average 
larger than the ones in the negative control, even if there 
was not a statistical significant difference. We propose that 
the loss of immunogenicity of this protocol is due to the 24 
h post-PDT incubation previous to generation of the vac-
cine. The immunogenic signals delivery pattern can be 
divided in three phases: the decision phase, when CRT is 
translocated to the membrane within few hours; the process-
ing phase, when HMGB1 is released within 18 h after ICD 
induction, as well as the release of ATP; and the effector 
phase, when DCs elicit T cell responses.2 So, during the 
post-PDT incubation of 24 h, the immunogenic signals 
expected to be produced on 4T1 cells by PDT (i.e., presence 
of DAMPs) may have already been released into the growth 
medium or destroyed with the cell contents, being discarded 
later when isolating the cells to generate the vaccines. Fur-
thermore, the additional procedure was unable to eliminate 
the risk of tumour formation due to the vaccine, in the 
Apoptosis/UV and UV control groups. The vaccine did not 
cause tumour development in the Necrosis/UV group but, 
taking into account the lack of immunogenicity of the vac-
cines, we suggest that this is a result of the protocol for 
Necrosis/UV originating near 100% cell death, unlike the 
former treatment groups. 
The analysis from the results obtained, lead to some changes 
in the protocol. The 4T1 cell line was changed to the mice 
colon carcinoma CT26 line, which is poorly to moderately 
immunogenic34 but less aggressive than the mammary tu-
mour line. The in vitro PDT procedure for this cell line was 
relatively stronger (incubation with 4.21 ȝM of redaporfin, 
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and irradiation of 0.35 J/cm2) supporting the fact that this 
cell line is more resistant to in vitro PDT.7 Another impor-
tant alteration to the protocol was the reduction of incuba-
tion time after PDT, from 24 h to 4 h. This had the purpose 
of taking advantage of the spatiotemporal sequence in ICD2 
following PDT, and have already some cytotoxicity to de-
crease the chance of developing a tumour due to the vaccine. 
For this optimized protocol we focused in only inducing 
apoptosis to generate the vaccines, which was the type of 
cell death that showed some effect in the beginning of the in 
vivo evaluation of 4T1 whole-cell vaccines, and is the type 
of treatment-induced cell death known to be associated with 
ICD.2,18 This protocol intended to evaluate the efficiency of 
two different cell densities, 500,000 and 300,000 CT26 
treated cells per vaccine, intending to solve the problem of 
secondary tumour generated by the vaccines. Animals from 
both groups were still able to develop a tumour in the left 
flank. Even so, there seems to be a difference between the 
PDT500 group, where besides the single mouse that acted as “vaccinated”, all the other animals developed secondary 
tumour from the vaccine; and the PDT300 group where 2 out 
5 were did not have tumours caused by vaccination. This 
indicates that the number of cells in the vaccine is one of the 
factors to take into account for further optimization: inocula-
tion of smaller number of cells (decrease the chances of 
generating tumours) more times (increase the vaccine effi-
ciency with a cumulative effect). 
The positive control used for comparison was MTX, also 
known to be immunogenic.21 We tried to induce the same 
level of cell death obtained with in vitro PDT protocol for 
CT26 by incubating the cells with 5 ȝM of MTX for 24 h. 
However, this was not enough to induce more than 30–40% 
of CT26 dead/dying cells by apoptosis, which concerned us 
in term of generating secondary tumours from the vaccine. 
But after following the in vivo experiment, this proved to be 
the only vaccination group where none of the animals had 
tumours on the vaccination site. Taking into account that the 
number of viable cells in these vaccines was clearly superior 
to the other vaccination groups, this either shows some 
immunogenic effect in the vaccination site, or it simply 
means that after 24 h the cells were still dying. 
The in vivo evaluation of tumour growth in response to the 
PDT-generated vaccine, while it did not have statistical 
difference, showed an improvement from the previous pro-
tocol with 4T1 cells. Animals that were inoculated with 
treated CT26 cells (PDT and MTX) were in average smaller 
than the ones in the negative control. In the PDT300 group, 
the curve of tumour growth did not show much difference 
when compared with the control group. So even if the 
smaller number of cells in the vaccines has an effect in the 
development of secondary tumours in the left flank, the 
decrease in number of cells also decreased the effect shown 
by the curve of tumour growth in the PDT500 group. PDT500 
vaccines produced similar results to the MTX vaccines, in 
the progression of average tumour growth. The results from 
these vaccination groups seem to be comparable to the work 
of Korbelik and Sun,26 though with therapeutic vaccines 
instead of prophylactic, they were able to generate vaccines 
that produced differences up to 400 mm3 between PDT-
generated vaccines and untreated controls, in the span of 13 
days after treating the tumour. In our protocol, differences of 
300 to 400 mm3 between the PDT500 and the control groups 
can also be seen in the 3rd week after the tumour challenge, 
proposing that there has some immunogenic effect. The 
MTX group was the only one to show statistical significant 
difference to the control group (p < 0.05) on day 28. How-
ever, this result is not totally accurate because the control 
group only had a n = 2, and this difference was not seen 
before or after this single event. This behaviour after MTX 
vaccination is different from what is shown in the study 
published by Garg et al.18 where ≈ 75% of the mice vacci-
nated with MTX-treated CT26 cells were able to remain 
tumour-free during the duration of the experiment (20 – 30 
days). This is possibly related to the differences in the pro-
tocols to generate the vaccines. 
CONCLUSION 
In the protocol for PDT-generated 4T1 whole-cell vaccines, 
the immunogenicity is lost after 24h. Instead of demonstrat-
ing a slower tumour growth, the average of tumour volumes 
of animals from the treatment groups was superior to the 
ones from the control group. Understanding this loss of 
immunogenicity allowed us to adjust the protocol by reduc-
ing the post-PDT incubation time. 
With the protocol for PDT-generated CT26 whole-cell vac-
cines, the results from the treatment groups showed im-
provement when compared to the control groups: the aver-
age of tumour volumes from treatment groups was lower, 
indicating the presence of immunogenicity, but not enough 
to have significant statistical difference. Even if the change 
to a slightly more immunogenic cell line may have influence 
in this result, we believe that the decrease of incubation time 
after in vitro PDT held a more important role. By reducing 
the incubation of 24h to 4h, we were able to vaccinate 
dead/dying cells in the process of releasing/exposing 
DAMPs (that was finished in vivo after inoculating the 
vaccine), instead of vaccinating dead cells that had already 
finished this process in vitro and lost the ability to stimulate 
the mice immune system after inoculation. 
This study initiated the optimization of a protocol to gener-
ate whole-cell antitumour vaccines using PDT with redapor-
fin. Although we did not reach an optimal protocol, it has 
the opportunity to be exploited more thoroughly, and to 
analyse the possible alterations in type of cell line used, 
number of cells vaccinated, or post-PDT incubation times, 
that can still be optimized and combined with other strate-
gies to potentiate systemic PDT. 
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 i 
SUPPLEMENTARY INFORMATION 
Preparation of the reagents 
RPMI growth medium 
The RPMI growth medium is the recommended growth medium for the 4T1 cell line. It was prepared by dissolving 10.4 g of 
RPMI-1640, 2.4 g of HEPES, and 2.0 g of sodium bicarbonate in 890 mL of milli-Q water supplemented with 100 mL of previ-
ously inactivated FBS (10%) and 10 mL of PenStrep (1%), per litre. The mixture was stirred until a homogeneous solution was 
obtained. Solution was filtered, inside the laminar hood, through a nitrocellulose filter (GVS Life Science) with a porosity of 0.2 
μm. RPMI was kept refrigerated, at 4ºC. 
 
DMEM growth medium 
The DMEM growth medium is the recommended growth medium for the CT26 cell line. It was prepared by dissolving 13.4 g of 
DMEM, 5.96 g of HEPES, and 3.7 g of sodium bicarbonate in 890 mL of milli-Q water supplemented with 100 mL of previously 
inactivated FBS (10%) and 10 mL of PenStrep (1%), per litre. The mixture was stirred until a homogeneous solution was obtained. 
Solution was filtered, inside the laminar hood, through a nitrocellulose filter (GVS Life Science) with a porosity of 0.2 μm. DMEM 
was kept refrigerated, at 4ºC. 
 
PBS 
A stock of PBS (10x) was prepared by dissolving 1.0 g of potassium phosphate dibasic, 1.0 g of potassium chloride, 5.75 g of sodi-
um phosphate dibasic, and 40.0 g of sodium chloride in 500 mL of milli-Q. PBS (10x) was stored at room temperature. 
The PBS solution was prepared from the dilution of PBS (10x) in milli-Q water. PBS was filtered, inside the laminar hood, through 
a nitrocellulose filter (GVS Life Science) with a porosity of 0.2 μm. PBS was kept refrigerated, at 4ºC. 
To prepare PBS Ca/Mg (used to wash CT26 cell between passages), the PBS solution was supplemented with 0.133 g of calcium 
chloride dehydrate and 0.1 g of magnesium chloride hexahydrate, before filtering the solution. PBS Ca/Mg was kept refrigerated, at 
4ºC. 
 
Trypsin solution 
Trypsin solution (1x) was used to detach cells for passaging. It was prepared by diluting the Trypsin-EDTA solution 10x (obtained 
from Sigma-Aldrich) in PBS. Trypsin was kept refrigerated, at 4ºC. 
 
FBS inactivation 
Thaw the FBS solution at room temperature, and complete the process in a water bath at 37ºC for 10 minutes. Afterwards, inacti-
vate the serum at 56ºC for 30 minutes, taking into account that all the serum has to be at 56ºC and that it needs to be stirred 4x 
times during the inactivation. Then, in a sterile environment, the inactivated FBS is divided and transferred in smaller volumes into 
several conical tubes which would be stored at -20ºC. 
 
Trypan Blue dye 
Trypan Blue dye solution was used to determine cell density by discriminating viable cells (white round appearance) from dead 
cells (dyed blue), since the dye presents a strong blue colour that only colours cells with damaged membrane. The dye solution was 
prepared by dissolving 40 mg of Trypan Blue purchased from Sigma-Aldrich in 10 mL of PBS solution, and then filtering the solu-
tion in a sterile environment. Trypan Blue was stored at room temperature. 
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Figures and Schemes 
 
 
Figure 1. Molecular structure of: (A) the photosensitizer redaporfin (adapted from Krzykawska et al.), and (B) MTX (adapted from the 
Sigma-Aldrich website, http://www.sigmaaldrich.com/catalog/product/sigma/m6545?lang=pt&region=PT; last visited at 13h30, on the 25th 
of August, 2015). 
 
 
 
 
Figure 2. Normalized absorption spectra of redaporfin in the different solvents used during the project. 
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Scheme 1. Schematic representation of the steps used to generate the 4T1 whole-cell vaccines 
 
(A) In vitro PDT protocol. (B) Protocol to isolate apoptotic/necrotic cells after PDT, for the UV irradiation. (C) Protocol to isolate 
cells that followed the steps 1-6 from Scheme 1A, for the UV irradiation – UV control group. 
 
 
 
 
Figure 3. (A) Structure improvised to irradiate the cells using the X-ray generator. The tube containing the pellet of 4T1 cells was glued to 
the head of a tack, which in turn was attached to a piece of plasticine (placed as seen in A.1) to ensure that the cells had enough height to 
be in the path of the X-ray irradiation, and then covered with piece A.2. (B) The X-ray generator working at the conditions used for the 
irradiation. 
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Figure 4. Arrangement set to irradiate the cells using a picosecond laser. The laser pulses leave the port (1), are reflected in the mirror (2), 
and reach the pellet of cell in the bottom of the tube (3). For the last part, it is important to take notice that the lid has to be open during the 
irradiation (plastic is not transparent to 266 nm wavelength), and that the surface of the pellet has to be completely covered by the area of 
the laser pulses. 
 
 
 
Scheme 2. Schematic representation of the steps used to generate the CT26 whole-cell vaccines using PDT 
 
(A) In vitro PDT protocol. (B) Protocol to isolate the apoptotic cells after PDT and generate the vaccines. 
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Scheme 3. Schematic representation of the steps used to generate the CT26 whole-cell vaccines MTX 
 
(A) In vitro MTX protocol. (B) Protocol to isolate the apoptotic cells after MTX incubation and generate the vaccines. 
 
 
 
 
Figure 5. Viability of 300,000 4T1 cells, 48h after UV irradiation: (A) 0.78 J, (B) 1.56 J, (C, D) 3.90 J, (E) 7.80 J, and (F) 15.6 J. The 
arrows indicate live cells. 
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Figure 6. Viability of 3x106 4T1 cells with fluorescent assays, 24h after UV irradiation: (A) 12.0 J; (B) 18.0 J; (C) 27.0 J; and (D) 36.0 J. 
Viability of two different irradiation protocols for UV control group with fluorescent assays: (E) 3x106 4T1 cells were irradiated 18 J, re-
dispersed in PBS, centrifuged at 3000 rpm for 5 min, and irradiated with more 18 J after discarding the supernatant; (F) two pellets of 
1.5x106 4T1 cells were irradiated with 18.0 J of UV radiation. The fluorescent dyes are Hoechst in blue, and PI in red. 
 
Figure 7. Viability of CT26 cells, 24h after PDT protocol. (A) Cells from the PDT500 group. (B) Stained cells from the PDT500 group. (C) 
Cells from the PDT300 group. (D) Stained cells from the PDT300 group. The fluorescent dyes are Hoechst in blue, and PI in red. 
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Tables 
 
Table 1. In vitro PDT conditions for 4T1 cells to modulate type of cell death and ROS factor associated 
[Redaporfin] 
(μM) 
Light Dose 
(J/cm2) Type of cell death ROS factor 
0.21 0.05 Apoptosis ↓↓↓ 0.0105 
0.21 0.10 Apoptosis ↓↓↓ 0.0211 
0.21 0.15 Apoptosis ↓↓ 0.0316 
0.21 0.20 Apoptosis ↓↓ 0.0421 
0.21 0.25 Apoptosis ↓ 0.0527 
0.21 0.30 Apoptosis ↓ 0.0632 
0.42 0.25 Apoptosis 0.1054 
0.42 0.30 Apoptosis 0.1264 
0.63 0.25 Apoptosis 0.1581 
1.26 0.15 Apoptosis 0.1897 
0.63 0.30 Apoptosis 0.1897 
0.63 0.35 Apoptosis; Necrosis ↓↓ 0.2213 
1.05 0.30 Necrosis; Apoptosis ↓↓ 0.3161 
1.26 0.30 Apoptosis ↓↓ 0.3793 
1.05 0.40 Necrosis 0.4215 
1.26 0.40 Apoptosis ↓↓ 0.5058 
1.05 0.50 Necrosis 0.5269 
1.05 0.52 Necrosis 0.5479 
1.05 0.56 Necrosis 0.5901 
1.26 0.50 Apoptosis; Necrosis ↓↓ 0.6322 
1.05 0.60 Necrosis 0.6322 
2.11 0.60 Necrosis 1.2645 
0.63 2.00 Necrosis 1.2645 
2.11 0.70 Necrosis 1.4752 
2.11 0.80 Necrosis 1.6860 
1.26 2.00 Necrosis 2.5289 
1.05 3.00 Necrosis 3.1612 
1.26 3.00 Necrosis 3.7934 
2.11 5.00 Necrosis 10.5372 
2.11 6.00 Necrosis 12.6446 
2.11 7.00 Necrosis 14.7521 
The conditions underlined were the ones chosen for the PDT protocol. 
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Table 2. 4T1 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in ani-
mals from the Control group (PBS) 
Mouse 
no. 
 Day 14  Day 21 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  3.4 3.4 19.652 16.303  5.0 4.1 42.025 53.566 
2  4.0 3.7 27.380 SEM  5.9 5.6 95.512 SEM 
3  2.9 2.6 9.8020 2.597  5.8 4.1 48.749 8.107 
4  3.2 3.1 15.376 N  5.1 4.6 53.958 N 
5  3.1 2.8 12.152 6  5.0 4.3 46.225 6 
6  3.2 2.9 13.456   4.3 4.2 37.926  
 
          
Mouse 
no. 
 
Day 28 
 
Day 33 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  7.0 6.7 157.115 164.229  8.1 7.8 246.402 313.345 
2  8.0 6.8 184.960 SEM  9.3 8.8 360.096 SEM 
3  9.4 6.7 210.983 12.099  10.0 8.9 396.050 30.365 
4  6.8 6.6 148.104 N  8.3 7.7 246.054 N 
5  6.8 6.1 126.514 6  8.1 7.8 246.402 6 
6  7.7 6.4 157.696   9.3 9.1 385.067  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. 
Table 3. 4T1 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in ani-
mals from the UV control group 
Mouse 
no. 
 Day 14  Day 21 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  3.9 3.5 23.888 28.141  6.6 4.5 66.825 148.497 
2  3.7 3.0 16.650 SEM  5.0 3.9 38.025 SEM 
3  5.4 5.3 75.843 11.029  9.3 6.7 208.739 75.045 
4  n/m n/m “0.000” N  5.6 3.7 38.332 N 
5  5.1 4.0 40.800 6  10.6 9.7 498.677 6 
6  3.2 2.7 11.664   5.9 3.7 40.386  
 
          
Mouse 
no. 
 
Day 28 
 
Day 33 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  8.0 5.9 139.240 329.704  10.2 7.3 271.779 405.841 
2  7.3 6.2 140.306 SEM  9.8 7.9 305.809 SEM 
3  12.3 6.9 292.802 163.902  14.9 10.3 790.371 98.864 
4  7.8 5.3 109.551 N  11.5 7.4 314.870 N 
5  15.3 12.2 1138.626 6     5 
6  12.2 7.9 157.696   11.1 7.9 346.376  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. “n/m” means non-
measurable (the tumour was palpable but could not be measured).  
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Table 4. 4T1 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in ani-
mals from the Necrosis/UV group 
Mouse 
no. 
 Day 14  Day 21 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  3.4 3.1 16.337 21.116  5.0 4.2 44.100 58.963 
2  3.7 3.0 16.650 SEM  4.3 4.2 37.926 SEM 
3  2.9 2.6 9.802 3.323  5.1 4.1 42.866 8.901 
4  5.3 3.1 25.467 N  6.4 5.2 86.528 N 
5  4.4 3.5 26.950 6  5.9 4.4 57.112 6 
6  4.6 3.7 31.487   7.4 4.8 85.248  
 
          
Mouse 
no. 
 
Day 28 
 
Day 33 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  6.5 6.4 133.120 280.325  8.9 7.2 230.688 402.076 
2  7.2 6.0 129.600 SEM  8.9 7.5 250.313 SEM 
3  9.9 7.9 308.930 32.537  11.5 10.2 598.230 67.589 
4  8.8 8.1 288.684 N  11.5 10.2 598.230 N 
5  7.4 6.5 156.325 6  9.4 8.2 316.028 6 
6  9.8 6.9 233.289   9.9 9.2 418.968  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. 
Table 5. 4T1 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in ani-
mals from the Apoptosis/UV group 
Mouse 
no. 
 Day 14  Day 21 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  n/m n/m “0.000” 10.595  6.6 4.5 66.825 86.990 
2  n/m n/m “0.000” SEM  5.0 3.9 38.025 SEM 
3  5.3 2.7 19.319 5.114  9.3 6.7 208.739 31.569 
4  3.3 3.0 14.850 N  5.6 3.7 38.332 N 
5  5.4 3.3 29.403 6  10.6 9.7 498.677 6 
6  0.0 0.0 0.000   5.9 3.7 40.386  
 
          
Mouse 
no. 
 
Day 28 
 
Day 33 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  8.0 5.9 139.240 239.446  10.2 7.3 271.779 375.276 
2  7.3 6.2 140.306 SEM  9.8 7.9 305.809 SEM 
3  12.3 6.9 292.802 40.409  14.9 10.3 790.371 72.310 
4  7.8 5.3 109.551 N  11.5 7.4 314.870 N 
5  15.3 12.2 1138.626 6     5 
6  7.7 6.4 157.696   11.1 7.9 346.376  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. “n/m” means non-
measurable (the tumour was palpable but could not be measured). 
 x 
Table 6. 4T1 whole-cell vaccine protocol: statistical analysis results using Student’s t-test to compare significant 
statistical difference between the treatment groups and the control. 
Day 14  Control  UV Control Necrosis/UV Apoptosis/UV 
Xm  16.303  28.141 21.116 10.595 
P (T ≤ t)    0.336 0.283 0.352 
N  6  6 6 6 
 
      
Day 21  Control  UV Control Necrosis/UV Apoptosis/UV 
Xm  53.566  148.497 58.963 86.990 
P (T ≤ t)    0.264 0.663 0.345 
N  6  6 6 6 
 
      
Day 28  Control  UV Control Necrosis/UV Apoptosis/UV 
Xm  164.229  329.704 280.325 239.446 
P (T ≤ t)    0.360 0.251 0.125 
N  6  6 6 6 
 
      
Day 33  Control  UV Control Necrosis/UV Apoptosis/UV 
Xm  313.345  405.841 402.076 375.276 
P (T ≤ t)    0.404 0.270 0.466 
N  6  6 5 5 
Where: Xm is the mean of tumour volumes, P (T ≤ t) is the probability of the test value T being equal/inferior to the critical value t, N is 
the number of animals at the timepoint. 
 
  
 xi 
Table 7. CT26 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in 
animals from the Control group 
Mouse 
no. 
 Day 14  Day 17 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  n/m n/m “0.000” 60.237  6.1 4.9 73.231 193.053 
2  2.5 2.1 5.513 SEM  8.6 5.1 111.843 SEM 
3  9 8 288.000 56.961  13.6 10.2 707.472 129.381 
4  n/m n/m “0.000” N  4.5 3.6 29.160 N 
5 †     5     5 
6  2.9 2.3 7.671   4.5 4.4 43.560  
 
          
Mouse 
no. 
 
Day 21 
 
Day 24 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  8.6 6.5 181.675 429.874  14.1 9.2 596.712 614.062 
2  11.3 7.2 292.896 SEM  15.1 10.6 848.318 SEM 
3  14.8 13.4 1328.744 225.954     84.629 
4  11.5 5.8 38.786 N  15.3 8.6 565.794 N 
5 †     5     4 
6  6.8 6.7 81.648   10.3 9.3 445.424  
 
          
Mouse 
no. 
 
Day 28 
 
Day 31 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  16.0 11.9 1132.880 1054.350     1584.798 
2     SEM     SEM 
3     78.530      
4     N     N 
5 †     2     1 
6  12.9 12.3 1584.798   15.5 14.3 1584.798  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. “n/m” means non-
measurable (the tumour was palpable but could not be measured). 
†
 This animal was not inoculated with the tumour challenge 
  
 xii 
Table 8. CT26 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in 
animals from the MTX group 
Mouse 
no. 
 Day 14  Day 17 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  2.3 1.9 4.152 8.275  5.6 3.9 42.588 83.302 
2  0.0 0.0 0.000 SEM  5.2 3.7 35.594 SEM 
3  0.0 0.0 0.000 7.475  0.0 0.0 0.000 43.628 
4  4.7 4.4 45.496 N  6.8 6.7 152.626 N 
5  0.0 0.0 0.000 6  8.2 8.1 269.001 6 
6  0.0 0.0 0.000   0.0 0.0 0.000  
 
          
Mouse 
no. 
 
Day 21 
 
Day 24 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  6.7 4.5 67.838 245.668  9.7 7.9 302.689 442.602 
2  6.3 4.4 60.984 SEM  9.8 5.1 127.449 SEM 
3  3.9 3.0 17.550 118.199  6.0 4.3 55.470 202.244 
4  11.6 9.3 501.642 N  15.0 9.6 691.200 N 
5  12.0 10.9 712.860 6  14.7 13.5 1339.538 6 
6  6.5 5.9 113.133   6.8 6.4 139.264  
 
          
Mouse 
no. 
 
Day 28 
 
Day 31 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  10.7 9.0 433.350 421.747  15.7 9.2 664.424 641.053 
2  11.6 6.3 230.202 SEM  15.3 9.4 675.954 SEM 
3  8.6 5.7 139.707 165.780  10.6 6.8 245.072 150.724 
4     N     N 
5     4     4 
6  13.6 11.4 883.728   14.3 11.7 978.764  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint.  
  
 xiii 
Table 9 CT26 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in ani-
mals from the PDT500 group 
Mouse 
no. 
 Day 14  Day 17 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  0.0 0.0 0.000 54.515  0.0 0.0 0.000 95.168 
2  0.0 0.0 0.000 SEM  n/m n/m “0.000” SEM 
3  0.0 0.0 0.000 43.832  2.5 2.3 6.613 68.541 
4  8.6 7.9 268.363 N  11.0 8.7 416.295 N 
5  5.8 4.5 58.725 6  6.8 6.6 148.104 6 
6  0.0 0.0 0.000   0.0 0.0 0.000  
 
          
Mouse 
no. 
 
Day 21 
 
Day 24 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  0.0 0.0 0.000 229.816  0.0 0.0 0.000 336.079 
2  4.1 2.9 17.241 SEM  5.8 4.1 48.749 SEM 
3  5.7 4.9 68.429 138.737  10.4 7.2 269.568 161.814 
4  16.3 10.5 898.538 N     N 
5  8.4 7.6 242.592 6  13.2 11.6 888.096 5 
6  7.2 6.5 152.100   11.2 9.2 473.984  
 
          
Mouse 
no. 
 
Day 28 
 
Day 31 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  0.0 0.0 0.000 670.4923  0.0 0.0 0.000 324.750 
2  7.7 5.3 108.147 SEM  8.8 6.0 158.400 SEM 
3  12.8 9.6 589.824 295.067  14.8 10.5 815.850 249.771 
4     N     N 
5  16.6 13.7 1557.827 5     4 
6  16.3 11.6 1096.664       
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. “n/m” means non-
measurable (the tumour was palpable but could not be measured). 
  
 xiv 
Table 10. CT26 whole-cell vaccine protocol: measurements and statistics on the evaluation of tumour growth in 
animals from the PDT300 group 
Mouse 
no. 
 Day 14  Day 17 
  a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  5.0 4.0 40.000 11.703  6.5 4.9 78.033 93.819 
2  0.0 0.0 0.000 SEM  5.4 5.0 67.500 SEM 
3  0.0 0.0 0.000 7.931  8.2 6.5 173.225 24.592 
4 †  0.0 0.0 0.000 N  n/m n/m “0.000” N 
5  0.0 0.0 0.000 5  4.1 3.8 29.602 5 
6  3.4 3.3 18.513   7.7 5.6 120.736  
 
          
Mouse 
no. 
 
Day 21 
 
Day 24 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  10.3 8.1 337.892 411.285  11.8 11.4 766.764 694.250 
2  11.7 6.9 278.519 SEM  14.8 10.5 815.850 SEM 
3  13.5 11.2 846.720 138.969  16.3 12.8 1335.296 200.258 
4 †  6.4 4.7 70.688 N  7.5 5.6 117.600 N 
5  6.3 5.1 81.932 5  9.5 6.0 171.000 5 
6  8.2 5.7 133.209   11.1 8.3 382.340  
 
          
Mouse 
no. 
 
Day 28 
 
Day 31 
 
 a (mm) b (mm) Vol (mm3) Xm  a (mm) b (mm) Vol (mm3) Xm 
1  15.3 12.9 1273.037 892.447     786.662 
2     SEM     SEM 
3     229.387     249.675 
4 †  9.2 8.7 348.174 N     N 
5  11.6 9.1 480.298 3  11.9 9.5 536.988 2 
6  13.5 11.7 924.008   13.7 12.3 1036.337  
Where: a is the major axis of the tumour, b is the minor axis of the tumour, Vol is tumour volume (calculated using equation 4), Xm is 
the mean of tumour volumes, SEM, is the standard error of the mean, N is the number of animals at the timepoint. “n/m” means non-
measurable (the tumour was palpable but could not be measured). 
†
 This animal developed a secondary tumour from the vaccine that reached the 1.5cm before the challenge tumour had reached any of 
the endpoints. It was not accounted for the statistical analysis. 
  
 xv 
Table 11. CT26 whole-cell vaccine protocol: statistical analysis results using Student’s t-test to compare significant 
statistical difference between the treatment groups and the control. 
Day 14  Control  MTX PDT500 PDT300 
Xm  60.237  8.275 54.515 11.703 
P (T ≤ t)    0.424 0.948 0.446 
N  5  6 6 5 
 
      
Day 17  Control  MTX PDT500 PDT300 
Xm  193.053  83.3015 95.169 93.8191 
P (T ≤ t)    0.458 0.529 0.493 
N  5  6 6 5 
 
      
Day 21  Control  MTX PDT500 PDT300 
Xm  429.874  245.668 229.816 411.285 
P (T ≤ t)    0.497 0.475 0.946 
N  225.954  6 6 5 
 
      
Day 24  Control  MTX PDT500 PDT300 
Xm  614.062  442.602 336.079 375.276 
P (T ≤ t)    0.460 0.179 0.727 
N  4  6 5 5 
 
      
Day 28  Control  MTX PDT500 PDT300 
Xm  1054.35  421.747 670.492 892.447 
P (T ≤ t)    0.026 † 0.277 0.573 
N  2  4 5 3 
 
      
Day 31  Control  MTX PDT500 PDT300 
Xm  1584.798  641.053 3214.750 786.662 
P (T ≤ t)       
N  1  4 3 2 
Where: Xm is the mean of tumour volumes, P (T ≤ t) is the probability of the test value T being equal/inferior to the critical value t, N is 
the number of animals at the timepoint. 
†
 Significant statistical difference (P < 0.05) 
 

